ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie

详细信息    查看全文

• 作者：M. von Laffert^a ; ^{maximilian.von-laffert@charite.de} ; P. Schirmacher^b ; A. Warth^b ; W. Weichert^c ; R. Bü ; ttner^d ; R.M. Huber^e ; J. Wolf^f ; F. Griesinger^g ; M. Dietel^a ; Ch. Grohé ; ^h ; ^{Christian.Grohe@pgdiakonie.de}
• 关键词：ALK-Testing ; Non-small cell lung cancer (NSCLC) ; Immunohistochemistry (IHC) ; Fluorescence in-situ hybridisation (FISH)
• 刊名：Lung Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：103
• 期：Complete
• 页码：1-5
• 全文大小：885 K
• 卷排序：103

文摘

FISH and IHC are available as validated diagnostic procedures. At individual centers additional NGS-based procedures can be performed. ALK-IHC is at least equivalent to FISH for ALK-activation in NSCLC. Two validated antibodies (5A4 and D5F3) are presently available. Antibodies should be used according to the validation studies.